

NCIC CLINICAL TRIALS GROUP

INVESTIGATIONAL NEW DRUG COMMITTEE

OPEN MEETING AGENDA

Delta Chelsea, Toronto. Room: Churchill A

Friday April 27, 2012 ~ 13.30pm – 16.30pm

Chair: Dr. Kim Chi

IND Program Directors: Drs. Elizabeth Eisenhauer and Lesley Seymour

1:30 pm:	Welcome	Dr. Kim Chi
1:30 pm:	Background on MET inhibitors in the clinic (20')	Dr. Percy Ivy, NCI CTEP
	IND.197 foretinib in Triple Negative Breast Cancer (5')	Dr. Danny Rayson
	IND.198 foretinib + lapatinib HER2 + breast cancer phase I trial (5')	Dr. Stephen Chia
	IND.196 foretinib + erlotinib NSCLC phase I (5')	Dr. Natasha Leighl
2:05 pm	Challenges in Combining Targeted Agents	Dr. Lesley Seymour
2:25 pm	IND. 195: SB939 prostate cancer - Final clinical and CTC results (10')	Dr. Kim Chi
2:35 pm	COFFEE/TEA	
2:55 pm	IND.203 Pediatric phase I trial of SB939 (10')	Dr. Sylvain Baruchel
3:05 pm	IND.199 Temsirolimus cervix – final clinical and translational data (10')	Dr. Anna Tinker
3:15 pm	Mutational analysis of mTOR inhibitor endometrial trials (IND.160 A, B and IND.192)	Dr. Amit Oza
3:30 pm	IND.204 PX866 in Glioblastoma: Interim report (10')	Dr. Marshall Pitz
3:40 pm	Report on April 26 2012 NCIC CTG workshop: Addressing Strategies in Personalized Medicine	Dr. Janet Dancey
4:10 pm	Update on ongoing and planned IND trials	
4:30 pm	ADJOURN	

IND OPEN COMMITTEE MEETING OBJECTIVES

- To summarize aspects of recent developments in the understanding of molecular biology and therapeutics as these relate to specific malignancies and their therapeutic targets
- To describe and discuss results of recent Investigational New Drug studies conducted by the NCIC Clinical Trials Group
- To understand aspects new clinical trial methodologies in the field of early cancer drug development